Observational studyNature communications2020
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.
3 registry-linked trialsAbstract readObservational Study
In one paragraph
Observational study in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions: a Clinical Trial
Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma by Biopsy Specimens.
Who cites it
82 citing papers in PubMed.
- CNN3 promotes vascular smooth muscle cells proliferation and migration to deteriorate atherosclerosis by β-catenin signaling pathway.Atherosclerosis plus · 2026Article
- Chromatin regulator expression patterns predict prognosis and guide neoadjuvant therapy in esophageal squamous cell carcinoma.Fundamental research · 2026Article
- Global landscape of protein-coding and long non-coding RNA alternative splicing and regulation in the human esophageal squamous cell carcinoma.Cancer cell international · 2026Article
- Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives.Protein & cell · 2026Review
- CircSPARC promotes esophageal squamous cell carcinoma through an HNRNPC-EPN2 splicing axis that activates Wnt/β-Catenin signaling.Molecular cancer · 2026Article
- Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy.EMBO molecular medicine · 2026Article
- Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026Review
- CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway.Scientific reports · 2026Article
- Shared patterns of dysregulated gene expression across squamous cell carcinomas unveil predictors for prognosis and drug sensitivity.Scientific reports · 2026Article
- Evaluating deconvolution methods using real bulk RNA-expression data for robust prognostic insights across cancer types.Genome biology · 2026Article
- Preliminary examination of noncoding mutations of esophageal squamous cell carcinoma in African Americans.Frontiers in genetics · 2026Article
- Reshaping immune cell distribution with mRNA noncationic lipid nanoparticles for overcoming neoadjuvant chemo-immunotherapy resistance.Theranostics · 2026Article
- Construction of Metastasis Prediction Models and Screening of Anti-Metastatic Drugs Based on Pan-Cancer Single-Cell EMT Features.International journal of molecular sciences · 2025Article
- Hypermethylated USP44 deubiquitinates SENP2: a critical mechanism in esophageal cancer progression and a new target for intervention.Clinical epigenetics · 2025Article
- Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion.Biomarker research · 2025Article
- LncRNA HOXA11-AS promotes the cell proliferation, migration, invasion and inhibits cell apoptosis in esophageal squamous cell carcinoma.Scientific reports · 2025Article
- Systematic identification of regions where DNA methylation is correlated with transcription refines regulatory logic in normal and tumour tissues.Nucleic acids research · 2025Article
- Epigenetically-Upregulated CD98 Shed Light on the Precancerous Diagnosis and Prognosis Prediction of Esophageal Cancer.Cancer science · 2025Article
- ALDH18A1 has carcinogenic functions and regulates alternative splicing events of DNA repair-related genes in esophageal carcinoma cells.Scientific reports · 2025Article
- Regulatory mechanisms and clinical implications of PIWI-interacting RNAs (piRNAs) in major digestive tract cancers.Cancer cell international · 2025Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Wei Cao *Translational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China. caowei7@zzu.edu.cn.ORCID http://orcid.org/0000-0002-2851-4359
Hayan Lee *Department of Genetics, School of Medicine, Stanford University, CA, USA.ORCID http://orcid.org/0000-0003-0571-3192
Wei Wu *Department of Medicine, University of California San Francisco, San Francisco, CA, USA. wei.wu@ucsf.edu.ORCID http://orcid.org/0000-0002-6556-067X
Aubhishek Zaman *Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Sean McCorkleComputational Science Initiative, Brookhaven National Laboratory, Upton, NY, USA.
Ming YanBasic Medical College, Zhengzhou University, Zhengzhou, China.
Justin ChenDepartment of Genetics, School of Medicine, Stanford University, CA, USA.
Qinghe XingInstitutes of Biomedical Sciences and Children's Hospital, Fudan University, Shanghai, China.
Nasa Sinnott-ArmstrongDepartment of Genetics, School of Medicine, Stanford University, CA, USA.ORCID http://orcid.org/0000-0003-4490-0601
Hongen XuPrecision Medicine Center, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
M Reza SailaniDepartment of Genetics, School of Medicine, Stanford University, CA, USA.
Wenxue TangPrecision Medicine Center, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Yuanbo CuiTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Jia LiuTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Hongyan GuanTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Pengju LvTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Xiaoyan SunTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Lei SunTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Pengli HanTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Yanan LouTranslational Medical Center, Zhengzhou Central Hospital Affiliated Zhengzhou University, Zhengzhou, China.
Jing ChangJiangsu Mai Jian Biotechnology Development Company, Wuxi, China.
Jinwu WangDepartment of Pathology, Linzhou Cancer Hospital, Linzhou, China.
Yuchi GaoAnnoroad Gene Company, Beijing, China.
Jiancheng GuoPrecision Medicine Center, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Gundolf SchenkBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1240-9949
Alan Hunter ShainDepartment of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Fred G BiddleDepartment of Biological Sciences, University of Calgary, Calgary, Canada.
Eric CollissonDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Michael SnyderDepartment of Genetics, School of Medicine, Stanford University, CA, USA. mpsnyder@stanford.edu.ORCID http://orcid.org/0000-0003-0784-7987
Trever G BivonaDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.ORCID http://orcid.org/0000-0001-5734-4128
Funding
UCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Collin M Blakely · 2017 to 2026
$12.9MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MThe Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2MVisualization hub for genomics data exploration and translational discoveryU24CA210974 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI COLLISSON, ERIC, HAUSSLER, DAVID H · 2016 to 2020
$4.2MCharacterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7MRational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentR01CA169338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2013 to 2023
$3.4MGenomics and Functional Characterization of NF1-mutated Lung CancerR01CA227807 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2018 to 2022
$2.8MThe structural and functional basis of MET exon 14 activation and acquired drug resistanceR01CA230263 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC, JURA, NATALIA · 2019 to 2023
$2.0MOptimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutationsR01CA239604 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2019 to 2023
$2.0MOptimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8MTailoring Therapy to Pancreatic Cancer SubtypesR01CA222862 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2018 to 2022
$1.8MCrucial Microenvironmental Cofactors for Pancreatic Cancer PathogenesisR01CA178015 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2014 to 2018
$1.5MNCI NIH HHS K22 CA217997NCI NIH HHS R01 CA169338NCI NIH HHS R01 CA178015NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS R01 CA222862NCI NIH HHS R01 CA227807NCI NIH HHS R01 CA230263NCI NIH HHS R01 CA239604NCI NIH HHS T32 CA108462NCI NIH HHS U01 CA217882NCI NIH HHS U24 CA210974NCI NIH HHS U54 CA224081NIH HHS S10 OD020141
Abstract
Epigenetic landscapes can shape physiologic and disease phenotypes. We used integrative, high resolution multi-omics methods to delineate the methylome landscape and characterize the oncogenic drivers of esophageal squamous cell carcinoma (ESCC). We found 98% of CpGs are hypomethylated across the ESCC genome. Hypo-methylated regions are enriched in areas with heterochromatin binding markers (H3K9me3, H3K27me3), while hyper-methylated regions are enriched in polycomb repressive complex (EZH2/SUZ12) recognizing regions. Altered methylation in promoters, enhancers, and gene bodies, as well as in polycomb repressive complex occupancy and CTCF binding sites are associated with cancer-specific gene dysregulation. Epigenetic-mediated activation of non-canonical WNT/β-catenin/MMP signaling and a YY1/lncRNA ESCCAL-1/ribosomal protein network are uncovered and validated as potential novel ESCC driver alterations. This study advances our understanding of how epigenetic landscapes shape cancer pathogenesis and provides a resource for biomarker and target discovery.
Indexed as
Epigenesis, GeneticGene Expression Regulation, NeoplasticAgedBiomarkers, TumorCell Line, TumorChromatin Immunoprecipitation SequencingCohort StudiesCpG IslandsDatasets as TopicDNA MethylationEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyEsophagusFemaleGenomicsBiomarkers, TumorHeterochromatinHistones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.